Kalash S S, Campbell E W, Young J D
Urology. 1983 Nov;22(5):486-92. doi: 10.1016/0090-4295(83)90225-x.
Coagulum pyelolithotomy without the use of thrombin is simplified by using single donor plasma, fresh frozen plasma, and "maxi-cryoprecipitate" (expanded cryoprecipitate) as sources of fibrinogen. The physical properties, including generation time, breaking point, and tensile strength were compared for different coagula. An illustrative case is presented for each fibrinogen source. The tensile strength of fresh frozen plasma coagulum was 15 per cent (17 Gm/cm2) and of maxi-cryoprecipitate 29 to 33 per cent (31-46 Gm/cm2) that of cryoprecipitate, but both were strong enough for clinical use. The preferred source of fibrinogen is cryoprecipitate followed by maxi-cryoprecipitate and fresh frozen plasma in that order. Twenty parts of fibrinogen to one part of 10 per cent calcium chloride provided the shortest generation time and the greatest tensile strength in each of the experiments, and is used exclusively by the authors at present. Single donor plasma is not recommended as a source of fibrinogen for coagulum generation clinically.
不使用凝血酶的凝块肾盂切开取石术通过使用单供体血浆、新鲜冷冻血浆和“大剂量冷沉淀”（扩容冷沉淀）作为纤维蛋白原来源得以简化。比较了不同凝块的物理特性，包括生成时间、断裂点和拉伸强度。针对每种纤维蛋白原来源都给出了一个示例病例。新鲜冷冻血浆凝块的拉伸强度为冷沉淀的15%（17克/平方厘米），大剂量冷沉淀的拉伸强度为冷沉淀的29%至33%（31 - 46克/平方厘米），但两者强度均足以用于临床。纤维蛋白原的首选来源依次为冷沉淀、大剂量冷沉淀和新鲜冷冻血浆。在每个实验中，20份纤维蛋白原与1份10%氯化钙搭配可提供最短的生成时间和最大的拉伸强度，目前作者仅使用这种组合。不建议将单供体血浆作为临床上生成凝块的纤维蛋白原来源。
